O'Dwyer Lung Lab

The David O’Dwyer Lab investigates Idiopathic Pulmonary Fibrosis (IPF), a progressive fatal lung disease. Our work aims to interrogate the interplay between the microbiome, immune system, and host physiology to form a more complete understanding of IPF. We utilize pre-clinical disease models, translational clinical studies, and statistical modeling in our approach. Our work is funded by the NHLBI and the Drews Research Fund.

microbiome Research

The microbiome, composed of bacteria, archaea, fungi, and viruses, is a dynamic ecosystem that occupies various niches of the body both inside and out. These microorganisms greatly outnumber your own cells, and any changes to this complex ecosystem can lead to profound effects on the host, including changes in mood, digestion, and the ability to fight disease. Our research examines the microbiomes of the lungs, gut, and mouth in the context of IPF. Using cutting-edge genomic sequencing techniques, we are uncovering the identity and function of key microbial players. We have identified links between the microbiome and host immune response, treatment heterogeneity, and disease outcomes. As the microbiome is a modifiable target, these findings have the potential to lead to novel clinical interventions. For a sneak peek into our findings: maintaining good oral hygiene and eating a healthy diet are some of the best things you can do for yourself!

Thermoneutrality Research

The thermoneutral zone (TNZ) of an organism is the ambient temperature range at which it does not have to expend extra energy to heat or cool itself. Humans largely exist within their TNZ due to clothing and modern HVAC systems. Experiencing temperatures outside this range can significantly alter host physiology and immunity. Our work is uncovering the importance of variable ambient temperatures in pulmonary fibrosis outcomes in clinical and preclinical models.

Translational Research

In addition to our preclinical modeling, we work with a wide variety of human samples including blood, stool and saliva. Combining our analysis of these samples with important data like lung function measures, medication history, and disease outcomes gives us a look into the human condition from a previously underdeveloped angle. We aim to use our findings on disease and treatment heterogeneity to enrich future clinical trials based on the microbiome.